Venkatraman Ganesh

Dr. Venkatraman Ganesh

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2010 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
RVRanganathan Vijayaraghavan
Ranganathan Vijayaraghavan
AIAleksey Izgorodin
Aleksey Izgorodin
VGVenkatraman Ganesh
Venkatraman Ganesh
MSMahadevan Surianarayanan
Mahadevan Surianarayanan
DMDouglas R. MacFarlane
Douglas R. MacFarlane

5 March 2012 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
VCV. Sarath Chandra
V. Sarath Chandra
GBGanga Baskar
Ganga Baskar
RSR. V. Suganthi
R. V. Suganthi
Elayaraja KolanthaiElayaraja Kolanthai
Elayaraja Kolanthai
MJM. I. Ahymah Joshy
M. I. Ahymah Joshy
SKS. Narayana Kalkura
S. Narayana Kalkura

1 December 2021 in Cancer Letters
Verified
Journal Article
Closed access
PYPoonam Yadav
Poonam Yadav
PSPriyanshu Sharma
Priyanshu Sharma
SSSandhya Sundaram
Sandhya Sundaram
VGVenkatraman Ganesh
Venkatraman Ganesh
ABAmal Kanti Bera
Amal Kanti Bera
DKDevarajan Karunagaran
Devarajan Karunagaran

23 October 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MRMathangi Ravi
Mathangi Ravi
SGSilpa Gampala
Silpa Gampala
GBGanga Baskar
Ganga Baskar
SPSurabhi Rohan Prasad
Surabhi Rohan Prasad
SRSwetha Raghavan
Swetha Raghavan
VGVenkatraman Ganesh
Venkatraman Ganesh
Triple-negative breast cancers represent an important clinical challenge, as these cancers do not respond to conventional endocrine therapies or other available targeted agents. Phycocyanin (PC), a natural, water soluble and non-toxic molecule is shown to have potent anti-cancer property. In this study, we determined the efficacy of PC as an anti-neoplastic agent in vitro on a series of breast cancer cell lines. We studied effects of PC in inducing DNA damage and apoptosis through western blot and qPCR. Also, anti-metastatic and anti-angiogenic properties were studied by classic wound healing and vasculogenic mimicry assays. We found that triple negative MDA-MB-231 cells were most sensitive to PC (IC50 : 5.98 ± 0.95 μM) as compared to other cells. They also showed decreased cell proliferation and reduced colony formation ability upon treatment with PC. Profile of Cell cycle analysis showed that PC caused G1 arrest which could be attributed to decreased mRNA levels of Cyclin E and CDK-2 and increased p21 levels. Mechanistic studies revealed that PC induced apoptosis as evident by increase in percentage of annexin positive cells, increase in γ-H2AX levels, and by changing the Bcl-2/Bax ratio followed by release of cytochrome C and increased Caspase 9 levels. MDA MB 231 cells treated with PC resulted in decreased cell migration and increased cell adhesive property and also showed anti-angiogenic effects. We also observed that PC suppressed cyclooxygenase-2 (COX-2) expression and prostaglandin E(2) production. All these biological effects of phycocyanin on MDA MB 231 cells could be attributed to decreased MAPK signaling pathway. We also observed that PC is non-toxic to non-malignant cells, platelets and RBC’s. Taken together, these findings demonstrate, for the first time, that PC may be a promising anti-neoplastic agent for treatment of triple negative breast cancers.

1 February 2012 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
VGVenkatraman Ganesh
Venkatraman Ganesh
RARamya
Ramya
SHShruthilaya
Shruthilaya
AKAkila
Akila
GAGanga
Ganga
GBGanga Baskar
Ganga Baskar
The focus on nanotechnology in cancer treatment and diagnosis has intensified due to the serious side effects caused by anticancer agents as a result of their cytotoxic actions on normal cells. This nonspecific action of chemotherapy has awakened a need for formulations capable of definitive targeting with enhanced tumor-killing. Nanooncology, the application of nanobiotechnology to the management of cancer, is currently the most important area of nanomedicine. Currently several nanomaterial-based drug-delivery systems are in vogue and several others are in various stages of development. Tumor-targeted drug-delivery systems are envisioned as magic bullets for cancer therapy and several groups are working globally for development of robust systems.

1 January 2008 in Cancer Letters
Verified
Journal Article
Closed access
Ajay P SinghAjay P Singh
Ajay P Singh
SBSangeeta Bafna
Sangeeta Bafna
KCKunal Chaudhary
Kunal Chaudhary
VGVenkatraman Ganesh
Venkatraman Ganesh
LSLynette Smith
Lynette Smith
SBSurinder Kumar Batra
Surinder Kumar Batra